| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.13 | 0.007 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.11 | 0.01 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.085 | 0.06 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.079 | 0.07 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | -0.08 | 0.07 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | -0.082 | 0.07 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | -0.071 | 0.09 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.073 | 0.1 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.077 | 0.1 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.063 | 0.1 |